title: [Caffeine citrate utilization for treatment of apnea in French neonatal units].
abstract: Caffeine citrate is commonly used for prophylaxis and treatment of apnea in preterm babies.
  
  
  OBJECTIVE
  To evaluate the use of caffeine citrate in french neonatal units.
  
  
  METHODS
  Postal survey in 100 neonatal units.
  
  
  RESULTS
  Answers were obtained from 81 units. Sixty-three units use systematic prophylactic treatment and the threshold of gestationnal age (weeks gestation) for this systematic treatment is 32 weeks. Caffeine citrate is administered as a loading dose of 20 mg/kg followed by a maintenance dose of 5 mg/kg in 95% of the units. Discontinuing the treatment occurs between 33 and 35 weeks in 37% of the units and between 35 and 37 weeks in 53%. Two third of neonatologits describe recurrent apnea beyond 37 weeks, with the need to continue treatment. Fourteen units sometimes discharge babies at home with ambulatory caffeine citrate treatment and discontinue treatment by 42 to 46 weeks'gestation. A mean duration of 5 days without apnea is required before discharge.
  
  
  CONCLUSIONS
  French teams respect "recommendations" concerning doses and duration without apnea before discharge. Indication of treatment, threshold for systematic treatment, duration of treatment and ambulatory treatment differ among teams.
authors.affiliation: Assistance Publique-Hôpitaux de Paris, Hôpital d'Enfants Armand-Trousseau, Service de Néonatologie, 26, Avenue du Dr-Arnold-Netter, 75771 Paris cedex 12, France. sarah.ducrocq@cch.aphp.fr
authors.forename: S
authors.initials: S
authors.lastname: Ducrocq
authors.forename: V
authors.initials: V
authors.lastname: Biran-Mucignat
authors.forename: F
authors.initials: F
authors.lastname: Lebas
authors.forename: J-J
authors.initials: JJ
authors.lastname: Baudon
authors.forename: F
authors.initials: F
authors.lastname: Gold
mesh_terms: D001049:Apnea / Q000188:drug therapy*; D002110:Caffeine / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002951:Citrates / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004363:Drug Utilization / Q000706:statistics & numerical data; D005602:France; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D007363:Intensive Care Units, Neonatal; D011795:Surveys and Questionnaires
chemical_list: D000697:Central Nervous System Stimulants; D002951:Citrates; D002110:Caffeine; C026189:caffeine citrate